The DOI matches its OpenAlex record; 26 of the 26 references it cites were found in a registry or an index.
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Abstract
PURPOSE: To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters. PATIENTS AND METHODS: Clinical data were analyzed for 124 patients, histopathologic slides for 67 primary tumors, and tissue specimens for 74 patients (38 primary and 36 metastatic tumors) with ACC and for 38 normal adrenal tissue samples. Molecular expression profiles were investigated by immunohistochemistry. The prognostic significance of 12 gross and histologic parameters in 67 primary ACCs was evaluated. Morphologic and protein expression patterns were correlated with disease-specific survival (DSS). Univariate influence of prognostic factors on DSS was analyzed by log-rank test and multivariate analysis by Cox regression. RESULTS: The median follow-up period was 4.7 years. Significant predictors of DSS included distant metastasis at time of initial presentation; venous, capsular, and adjacent organ invasion; tumor necrosis, mitotic rate, atypical mitosis, and mdm-2 overexpression. Five-year DSS by number (one to six) of adverse histologic parameters was as follows: one to two, 84%; three to four, 37%; more than four, 9% (P =.005). The phenotype Ki-67(-)p53(-)mdm-2(+)cyclinD1(-)Bcl-2(-)p21(-)p27(+) was observed in 83% of normal and 3% of malignant adrenal tissue (P =.01). Molecular phenotypic expression was more heterogeneous in malignant than in normal (10 v five phenotypes) adrenal tissue. CONCLUSION: Meticulous morphologic evaluation, mitotic count, and tumor stage are essential in determining prognosis for patients with ACC. Multimolecular phenotyping demonstrates that the molecular complexity and heterogeneity of these neoplasms are such that targeted therapy needs to be patient specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724
BCL-2 FAMILY: Regulators of Cell Death
Chao, D. T., & Korsmeyer, S. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.395 · Cited by 1,685
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920
Gerdes, J., Li, L., Schlueter, C. J., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., & Flad, H. D. (1991) · PubMed · Cited by 889
Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 823
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Tissue microarrays for gene amplification surveys in many different tumor types.
Schraml, P., Kononen, J., Bubendorf, L., Moch, H., Bissig, H., Nocito, A., Mihatsch, M. J., Kallioniemi, O., & Sauter, G. (1999) · PubMed · Cited by 433
Hoos, A., Urist, M. J., Stojadinovic, A., Mastorides, S., Dudas, M. E., Leung, D. H. Y., Kuo, D., Brennan, M. F., Lewis, J. J., & Cordon-Cardo, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64075-8 · Cited by 400
Self-citationSchulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366
Self-citationMorphologic characteristics of benign and malignant adrenocortical tumors
Slooten, H. V., Schaberg, A., Smeenk, D., & Moolenaar, A. J. (1985) · Cancer · doi:10.1002/1097-0142(19850215)55:4<766::aid-cncr2820550414>3.0.co;2-7 · Cited by 326
Richter, J., Wagner, U., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knönagel, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64592-0 · Cited by 242
p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies
Reincke, M. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.3.790 · Cited by 228
Mucci, N. R., Akdas, G., Manely, S., & Rubin, M. A. (2000) · Human Pathology · doi:10.1053/hp.2000.7295 · Cited by 182
Icard, P., Chapuis, Y., Andréassian, B., Bernard, A., & Proye, C. A. G. (1992) · PubMed · Cited by 179
Pathologic Features of Prognostic Significance for Adrenocortical Carcinoma After Curative Resection
Harrison, L. E., Gaudin, P. B., & Brennan, M. F. (1999) · Archives of Surgery · doi:10.1001/archsurg.134.2.181 · Cited by 117
Self-citationMeijer, C. J. L. M., van der Loo, E. M., van Vloten, W. A., van der Velde, E. A., Scheffer, E., & Cornelisse, C. J. (1980) · Cancer · doi:10.1002/1097-0142(19800601)45:11<2880::aid-cncr2820451127>3.0.co;2-# · Cited by 105
Cell proliferation and apoptosis in normal and pathologic human adrenal.
Sasano, H., Imatani, A., Shizawa, S., Suzuki, T., & Nagura, H. (1995) · PubMed · Cited by 83
Adrenal Cortical Neoplasms:A Study of 56 Cases
Evans, H. L., & Vassilopoulou‐Sellin, R. (1996) · American Journal of Clinical Pathology · doi:10.1093/ajcp/105.1.76 · Cited by 57
Expression of p53 in adrenocortical tumours: clinicopathological correlations
McNicol, A. M., Nolan, C. E., Struthers, A. J., Farquharson, M. A., Hermans, J., & Haak, H. R. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199702)181:2<146::aid-path744>3.0.co;2-7 · Cited by 56
Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms.
Nakazumi, H., Sasano, H., Iino, K., Ohashi, Y., & Orikasa, S. (1998) · PubMed · Cited by 56
Edgren, M., Eriksson, B., Wilander, E., Westlin, J.-E., Nilsson, S. F., & Öberg, K. (1997) · PubMed · Cited by 50
Tritos, N. A., Cushing, G. W., Heatley, G. J., & Libertino, J. A. (2000) · The American Surgeon · doi:10.1177/000313480006600115 · Cited by 48
ADRENAL CORTICAL CARCINOMA: A clinicopathological and Immunohistochemical Study of 91 Autopsy Cases
Nakano, M. (1988) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1988.tb01095.x · Cited by 23
Cited by
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“The mitotic rate was found to be an independent predictor of disease-free survival in adrenocortical carcinoma and is, in combination with the presence of venous invasion, correlated best with metastasizing behavior (312, 315).”
BackgroundAdrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Michalkiewicz, E., Sandrini, R., Figueiredo, B., Miranda, E. C. M., Caran, E., Oliveira-Filho, A. G., Marques, R., Pianovski, M. A. D., Lacerda, L., Cristofani, L. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.085 · Cited by 519
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Metadata
- Authors
- Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-02-15
- Volume
- 20
- Issue
- 4
- Pages
- 941-950
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2076710019
- Cited by
- 312
- References
- 26
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.